Merck Sharp & Dohme lodges cross appeal in Prevnar 13 vaccine patent spat

Allens 2021-01-25 4:33 pm By Miklos Bolza | Melbourne

Please login to bookmark

Drug giant Merck Sharp & Dohme has brought a cross appeal in its long-running intellectual property dispute with Pfizer’s Wyeth over the top selling Prevnar 13 pneumococcal vaccine.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au